The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT)

Henrik Wiggers, Lars Køber, Gunnar Gislason, Morten Schou, Mikael Kjær Poulsen, Søren Vraa, Olav Wendelbo Nielsen, Niels Eske Bruun, Helene Nørrelund, Malene Hollingdal, Anders Barasa, Morten Bøttcher, Karen Dodt, Vibeke Brogaard Hansen, Gitte Nielsen, Anne Sejr Knudsen, Jens Lomholdt, Kirsten Vilain Mikkelsen, Bartlomiej Jonczy, Jens Brønnum-SchouMonica Petronela Poenaru, Jawdat Abdulla, Ilan Raymond, Kiomars Mahboubi, Karen Sillesen, Kristine Serup-Hansen, Jette Sandberg Madsen, Søren Lund Kristensen, Anders Hostrup Larsen, Hans Erik Bøtker, Christian Torp-Petersen, Hans Eiskjær, Jacob Møller, Christian Hassager, Flemming Hald Steffensen, Bo Martin Bibby, Jens Refsgaard, Dan Eik Høfsten, Søren Mellemkjær, Finn Gustafsson

Research output: Contribution to journalJournal articlepeer-review

7 Citations (Scopus)
Original languageEnglish
JournalAmerican Heart Journal
Volume231
Pages (from-to)137-146
Number of pages10
ISSN0002-8703
DOIs
Publication statusPublished - Jan 2021

Fingerprint

Dive into the research topics of 'The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT)'. Together they form a unique fingerprint.

Cite this